Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions

Drug Safety

Volumn 39, Issue 10, 2016, Pages 925-943

  Slim, Mahmoud ^a   Medina Caliz, Inmaculada ^a,c   Gonzalez Jimenez, Andres ^a   Cabello, M Rosario ^a,c   Mayoral Cleries, Fermin ^b   Lucena, M Isabel ^a,c   Andrade, Raul J ^a,c,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ACUTE LIVER FAILURE; ALLERGIC REACTION; CONTROLLED CLINICAL TRIAL (TOPIC); DRESS SYNDROME; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; EPIDEMIOLOGICAL DATA; EXTRAPYRAMIDAL SYMPTOM; FEVER; FULMINANT HEPATIC FAILURE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; JAUNDICE; LIVER FAILURE; LIVER INJURY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SIDE EFFECT; TOXIC HEPATITIS; WEIGHT GAIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EFFECTS; LIVER; SAFETY;

ANTIPSYCHOTIC AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; LIVER; SAFETY;

EID: 84979567264     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-016-0436-7     Document Type: Review

References (153)

1. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(Suppl 7):29–40.
2. Szkultecka-Debek M, Walczak J, Augustynska J, Miernik K, Stelmachowski J, Pieniazek I, et al. Epidemiology and treatment guidelines of negative symptoms in schizo-phrenia in Central and Eastern Europe: a literature review. Clin Pract Epidemiol Ment Health. 2015;11:158–65.
3. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–45.
4. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383–402.
5. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495–500.
6. Golan DE, Tashjian AH. Principles of pharmacology: the pathophysiologic basis of drug therapy. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
7. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
8. McDonagh M, Peterson K, Carson S, Fu R, Thakurta S. Drug class reviews: atypical antipsychotic drugs: final update 3 report. Portland: Oregon Health and Science University; 2010.
9. Anderson IM, McAllister-Williams RH. Fundamentals of clinical psychopharmacology. 4th ed. Portland: Taylor & Francis Inc.; 2015.
10. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314(17):1818–31.
11. Olfson M, King M, Schoenbaum M. Antipsychotic treatment of adults in the United States. J Clin Psychiatry. 2015;76(10):1346–53.
12. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–84.
13. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703–11.
14. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
15. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63–101.
16. Larrey D, Ripault M-P. Chapter 25—hepatotoxicity of psychotropic drugs and drugs of abuse A2. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Boston: Academic Press; 2013. p. 443–62.
17. Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol. 2012;35(5):244–53.
18. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology. 2015;148(7):1340–52 e7.
19. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012;107(9):1380–7.
20. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study G. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52(6):2065–76.
21. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25.e1–3.
22. Bessone F, Hernandez N, Sanchez J, et al. A comparative analysis of the Spanish and Latin-American prospective drug-induced liver injury (DILI) networks. Hepatology. 2015;62(1):Abstract 504A.
23. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105(11):2396–404.
24. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.
25. Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis. 2008;66(2):143–5.
26. Andrade RJ, Ortega-Alonso A, Lucena MI. Drug-induced liver injury clinical consortia: a global research response for a worldwide health challenge. Expert Opin Drug Metab Toxicol. 2016;12(6):589–93.
27. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33(6):503–22.
28. Bjornsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
29. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, et al. Drug-induced liver injury: results from the hospital-based Berlin Case–Control Surveillance Study. Br J Clin Pharmacol. 2015;79(6):988–99.
30. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology. 1999;29(5):1347–51.
31. Lucena MI, Garcia-Cortes M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008;22(2):141–58.
32. Chiappedi M, de Vincenzi S, Bejor M. Nutraceuticals in psychiatric practice. Recent Pat CNS Drug Discov. 2012;7(2):163–72.
33. Bello N, Winit-Watjana W, Baqir W, McGarry K. Disclosure and adverse effects of complementary and alternative medicine used by hospitalized patients in the North East of England. Pharm Pract (Granada). 2012;10(3):125–35.
34. Weber NS, Cowan DN, Millikan AM, Niebuhr DW. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv. 2009;60(8):1059–67.
35. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–82.
36. Fontanella CA, Warner LA, Phillips GS, Bridge JA, Campo JV. Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002–2008. Psychiatr Serv. 2014;65(11):1332–40.
37. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28(2):99–112.
38. Grundmann M, Kacirova I, Urinovska R. Therapeutic drug monitoring of atypical antipsychotic drugs. Acta Pharm. 2014;64(4):387–401.
39. Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug–drug interactions involving P-glycoprotein. CNS Drugs. 2012;26(11):959–73.
40. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug–drug interactions. Curr Drug Metab. 2008;9(5):410–8.
41. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006;58(7):871–85.
42. English BA, Dortch M, Ereshefsky L, Jhee S. Clinically significant psychotropic drug–drug interactions in the primary care setting. Curr Psychiatry Rep. 2012;14(4):376–90.
43. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury N. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–70.
44. Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry. 2011;168(2):212–3.
45. Lucena MI, Kaplowitz N, Hallal H, Castiella A, Garcia-Bengoechea M, Otazua P, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):820–7.
46. Novartis. Clozaril (clozapine): US prescribing information. 2015. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0c6f5f-b906-4c8f-8580-3939a476a1c1. Accessed 15 Feb 2016.
47. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992;63(1):51–70.
48. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997;17(4):314–7.
49. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology. 1997;112(5):1707–9.
50. Chang A, Krygier DS, Chatur N, Yoshida EM. Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol. 2009;23(5):376–8.
51. Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology (Berl). 1989;99(Suppl):S97–100.
52. Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia–a retrospective study of 387 patients. Psychopharmacology (Berl). 1989;99(Suppl):S73–6.
53. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(3):537–44.
54. Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21(3):305–10.
55. Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine rechallenge after marked liver enzyme elevation. J Clin Psychopharmacol. 1994;14(6):425–6.
56. Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med. 2004;34(1):83–9.
57. Brown CA, Telio S, Warnock CA, Wong AH. Clozapine toxicity and hepatitis. J Clin Psychopharmacol. 2013;33(4):570–1.
58. Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol. 1998;13(2):95–8.
59. Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol. 1997;17(2):120–1.
60. Chaplin AC, Curley MA, Wanless IR. Re: Recent case report of clozapine-induced acute hepatic failure. Can J Gastroenterol. 2010;24(12):739–40 (author reply 41).
61. Schmidt G, Borsch G, Muller KM, Ricken D. Clozapine-induced cholestatic liver lesions. A case study. Dtsch Med Wochenschr. 1987;112(21):844–6.
62. Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment. Am J Psychiatry. 1993;150(6):985–6.
63. Thatcher GW, Cates M, Bair B. Clozapine-induced toxic hepatitis. Am J Psychiatry. 1995;152(2):296–7.
64. Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapine-induced toxic hepatitis with skin rash. J Psychopharmacol. 2005;19(1):107.
65. Kang SH, Lee JI. Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment. Clin Psychopharmacol Neurosci. 2013;11(2):103–5.
66. European Medicines Agency. Risperdal and associated names. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_30/WC500007976.pdf. Accessed 15 Feb 2016.
67. Janssen. Risperdal (risperidone): US prescribing information. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020272s077,020588s065,021346s055,021444s051lbl.pdf. Accessed 15 Feb 2016.
68. Radzik J, Grotthus B, Leszek J. Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment—case report. Psychiatr Pol. 2005;39(2):309–13.
69. Wright TM, Vandenberg AM. Risperidone- and quetiapine-induced cholestasis. Ann Pharmacother. 2007;41(9):1518–23.
70. Llinares Tello F, Hernandez Prats C, Bosacoma Ros N, Perez Martinez E, Climent Grana E, Navarro Polo JN, et al. Acute cholestatic hepatitis probably associated with risperidone. Int J Psychiatry Med. 2005;35(2):199–205.
71. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol. 1999;9(2):93–8.
72. Erdogan A, Karaman MG, Ozdemir E, Yurteri N, Tufan AE, Kurcer MA. Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. J Child Adolesc Psychopharmacol. 2010;20(5):407–13.
73. Karaman MG, Erdogan A, Tufan E, Yurteri N, Ozdemir E, Ankarali H. Liver function tests in children and adolescents receiving risperidone treatment for a year: a longitudinal, observational study from Turkey. Int J Psychiatry Clin Pract. 2011;15(3):204–8.
74. Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol. 2005;20(3):173–6.
75. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1255–60.
76. Moylan CA, Suzuki A, Papay JI, Yuen NA, Ames M, Hunt CM. A pre-marketing ALT signal predicts post-marketing liver safety. Regul Toxicol Pharmacol. 2012;63(3):433–9.
77. Legaz Huidobro ML, Gonzalez Carro P, Perez Roldan F, Soto Fernandez S, de Pedro Esteban A, Cuesta Dominguez R. Autoimmune hepatitis after risperidone-induced cholestatic hepatitis. Gastroenterol Hepatol. 2005;28(3):135–6.
78. Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol. 2014;6(4):160–8.
79. Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale. 2002;28(6 Pt 1):542–51.
80. Narasimhan M, Bruce TO, Masand P. Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2007;3(5):579–87.
81. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177–93.
82. Lilly. Zyprexa (olanzapine): EMA summary of product characteristics. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000115/WC500055207.pdf. Accessed 15 Feb 2016.
83. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154(4):457–65.
84. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58(Suppl 10):13–7.
85. Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003;42(10):1227–33.
86. Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci. 2001;321(2):156–8.
87. Kolpe M, Ravasia S. Effect of olanzapine on the liver transaminases. Can J Psychiatry. 2003;48(3):210.
88. Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1163–6.
89. Lui SY, Tso S, Lam M, Cheung EF. Possible olanzapine-induced hepatotoxicity in a young Chinese patient. Hong Kong Med J. 2009;15(5):394–6.
90. Dominguez-Jimenez JL, Puente-Gutierrez JJ, Pelado-Garcia EM, Cuesta-Cubillas D, Garcia-Moreno AM. Liver toxicity due to olanzapine. Rev Esp Enferm Dig. 2012;104(11):617–8.
91. Tchernichovsky E, Sirota P. Hepatotoxicity, leucopenia and neutropenia associated with olanzapine therapy. Int J Psychiatry Clin Pract. 2004;8(3):173–7.
92. Hung CC, Wei IH, Huang CC. Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1574–5.
93. Sanofi-Aventis. Amisulpride: UK prescribing information. 2010. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con263937.pdf. Accessed 22 March 2016.
94. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17(1):1–13.
95. Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205–11.
96. European Medicine Agency. Committee for proprietary medicinal products opinion following an article 36 referral: Sertindole. 2002. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sertindole_36/WC500011855.pdf Accessed 20 March 2016.
97. Kasper S, Moller HJ, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci. 2010;260(1):59–68.
98. H. Lundbeck A/S. Safety study of sertindole versus risperidone under normal conditions of use (SCoP) [NCT00856583]. 2014. https://clinicaltrials.gov/ct2/show/results/NCT00856583?sect=X30156#evnt. Accessed 20 March 2016.
99. Food and Drug Administration Psychopharmacology Drugs Advisory Committee. Briefing book: Serdolect (sertindole) tablets. 2009. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4424b1-01-FDA.pdf. Accessed 20 March 2016.
100. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012;26(5):435–60.
101. AstraZeneca. Seroquel XR (quetiapine fumarate): US prescribing information. 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022047s011s016s017s019s022lbl.pdf. Accessed 21 Feb 2016.
102. AstraZeneca. Seroquel (quetiapine fumarate). 2003. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022047s011s016s017s019s022lbl.pdf. Accessed 21 Feb 2016.
103. El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol. 2004;16(12):1415–8.
104. Shpaner A, Li W, Ankoma-Sey V, Botero RC. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol. 2008;20(11):1106–9.
105. Klinke JA, Shapira SC, Akbari E, Holmes DT. Quetiapine-associated cholestasis causing lipoprotein-X and pseudohyponatraemia. J Clin Pathol. 2010;63(8):741–3.
106. Al Mutairi F, Dwivedi G, Al Ameel T. Fulminant hepatic failure in association with quetiapine: a case report. J Med Case Rep. 2012;6:418.
107. Lin CH, Liu CM, Huang WL. Quetiapine-induced hepatocellular damage. Psychosomatics. 2012;53(6):601–2.
108. Pfizer. Geodon (ziprasidone): US prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020825s054,020919s041,021483s014lbl.pdf. Accessed 15 Feb 2016.
109. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491–505.
110. Arato M, O’Connor R, Meltzer HY, Group ZS. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207–15.
111. Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009;54(1):46–54.
112. Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:77–85.
113. Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol. 2013;23(8):531–44.
114. Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121–5.
115. Gordon JS, Neyman KM, Wells RD, Chen SC. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). Cutis. 2012;89(4):180–2.
116. Kim MS, Kim SW, Han TY, Son SJ, Lee JH, Kim EJ. Ziprasidone-induced hypersensitivity syndrome confirmed by reintroduction. Int J Dermatol. 2014;53(4):e267–8.
117. Tsai CF, Tsai SJ, Hwang JP. Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient. Int J Geriatr Psychiatry. 2005;20(8):797–9.
118. Chan VC, La Grenade L, Diak IL, Levin RL. US Food and Drug Administration warning about the risk of drug reaction with eosinophilia and systemic symptoms with ziprasidone. J Clin Psychiatry. 2015;76(9):e1138–9.
119. Bristol-Myers Squibb. Abilify (aripiprazole): EMA summary of product characteristics. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000471/WC500020170.pdf. Accessed 15 Feb 2016.
120. Bristol-Myers Squibb. Abilify (aripiprazole): US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf. Accessed 15 Feb 2016.
121. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29(9):773–99.
122. Food and Drug Administration Department of Health and Human Services. New molecular entity follow-up: aripiprazole. 2008. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM185327.pdf. Accessed 1 March 2016.
123. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65(5):403–13.
124. Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769–79.
125. European Medicines Agency. EPAR summary for the public: paliperidone. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004066/WC500180640.pdf. Accessed 21 Feb 2016.
126. Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158–65.
127. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654.
128. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010(11):CD006633.
129. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006625.
130. Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig. 2015;12(2):242–8.
131. Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;14(4):286–92.
132. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14.
133. Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789–806.
134. Petrikis P, Tigas S, Tzallas AT, Papadopoulos I, Skapinakis P, Mavreas V. Parameters of glucose and lipid metabolism at the fasted state in drug-naive first-episode patients with psychosis: evidence for insulin resistance. Psychiatry Res. 2015;229(3):901–4.
135. Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 2015;35(7):1801–8.
136. Ng W, Kennar R, Uetrecht J. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol. 2014;27(7):1104–8.
137. Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.
138. Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry. 2011;72(4):458–63.
139. Zhang WV, Ramzan I, Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther. 2007;322(2):770–7.
140. Dragovic S, Venkataraman H, Begheijn S, Vermeulen NP, Commandeur JN. Effect of human glutathione S-transferase hGSTP1-1 polymorphism on the detoxification of reactive metabolites of clozapine, diclofenac and acetaminophen. Toxicol Lett. 2014;224(2):272–81.
141. Choi KH, Higgs BW, Weis S, Song J, Llenos IC, Dulay JR, et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry. 2009;9:57.
142. Wu Chou AI, Lu ML, Shen WW. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat. 2014;10:1585–7.
143. American Diabetes A, American Psychiatric A, American Association of Clinical E, North American Association for the Study of O. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res. 2004;12(2):362–8.
144. Canadian Diabetes Association Clinical Practice Guidelines Expert C, Robinson DJ, Luthra M, Vallis M. Diabetes and mental health. Can J Diabetes. 2013;37(Suppl 1):S87–92.
145. National Institute for Health and Clinical Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. 2014. https://www.nice.org.uk/guidance/cg178. Accessed 14 Feb 2016.
146. Poulin MJ, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry. 2005;50(9):555–62.
147. Gothefors D, Adolfsson R, Attvall S, Erlinge D, Jarbin H, Lindstrom K, et al. Swedish clinical guidelines–prevention and management of metabolic risk in patients with severe psychiatric disorders. Nord J Psychiatry. 2010;64(5):294–302.
148. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. Hoboken: Wiley; 2015.
149. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
150. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–83.
151. Liu Z, Tang Q, Wen J, Tang Y, Huang D, Huang Y, et al. Elevated serum complement factors 3 and 4 are strong inflammatory markers of the metabolic syndrome development: a longitudinal cohort study. Sci Rep. 2016;6:18713.
152. Palanca-Maresca I, Ruiz-Antoran B, Centeno-Soto G, Jimenez-Fernandez S, Garcia-Murillo L, Siles A, et al. SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. Springerplus. 2014;3:187.
153. Rahman SA, Bashton M, Holliday GL, Schrader R, Thornton JM. Small Molecule Subgraph Detector (SMSD) toolkit. J Cheminform. 2009;1(1):12.